skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance

Journal Article · · Communications Biology
 [1];  [2];  [1];  [1];  [3]; ORCiD logo [1]
  1. Gilead Sciences, Inc., Foster City, CA (United States)
  2. The Ohio State Univ., Columbus, OH (United States). The Ohio State Biophysics Program
  3. The Ohio State Univ., Columbus, OH (United States). The Ohio State Biophysics Program; Florida State Univ., College of Medicine, Tallahassee, FL (United States). Dept. of Biomedical Sciences

Emtricitabine (FTC) and lamivudine (3TC), containing an oxathiolane ring with unnatural (-)-stereochemistry, are widely used nucleoside reverse transcriptase inhibitors (NRTIs) in anti-HIV therapy. Treatment with FTC or 3TC primarily selects for the HIV-1 RT M184V/I resistance mutations. Here we provide a comprehensive kinetic and structural basis for inhibiting HIV-1 RT by (-)-FTC-TP and (-)-3TC-TP and drug resistance by M184V. (-)-FTC-TP and (-)-3TC-TP have higher binding affinities (1/Kd200-fold) Kd for the L-nucleotides and moderately higher (>9-fold) Kd for the D-isomers compared to dCTP. The M184V RT structure illustrates how the mutation repositions the oxathiolane of (-)-FTC-TP and shifts its triphosphate into a non-productive conformation.

Research Organization:
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
AC02-05CH11231
OSTI ID:
1624535
Journal Information:
Communications Biology, Vol. 2, Issue 1; ISSN 2399-3642
Publisher:
Springer NatureCopyright Statement
Country of Publication:
United States
Language:
English

References (43)

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. journal November 1992
Prospective Randomized Trial of Emtricitabine versus Lamivudine Short‐Term Monotherapy in Human Immunodeficiency Virus–Infected Patients
  • Rousseau, Franck S.; Wakeford, Charles; Mommeja‐Marin, Herve
  • The Journal of Infectious Diseases, Vol. 188, Issue 11 https://doi.org/10.1086/379667
journal December 2003
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study journal July 2005
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. journal April 1993
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. journal June 1993
Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection journal July 2000
Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins journal June 1996
Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase journal November 2003
Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1 journal July 1995
The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase journal April 1998
Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase journal August 1997
Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In Vitro journal January 1999
Tenofovir Resistance and Resensitization journal November 2003
Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TC journal August 1997
The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase 1 1Edited by A. R. Fersht journal July 2000
Human Immunodeficiency Virus Type-1 Reverse Transcriptase: CONTRIBUTION OF MET-184 TO BINDING OF NUCLEOSIDE 5′-TRIPHOSPHATE journal June 1996
Mechanistic Studies Examining the Efficiency and Fidelity of DNA Synthesis by the 3TC-Resistant Mutant (184V) of HIV-1 Reverse Transcriptase journal July 1999
Structural basis for the binding and incorporation of nucleotide analogs with L-stereochemistry by human DNA polymerase   journal July 2014
Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ journal June 2015
Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP journal September 1999
Pre-Steady-State Kinetic Analysis of the Incorporation of Anti-HIV Nucleotide Analogs Catalyzed by Human X- and Y-Family DNA Polymerases journal November 2010
Presteady State Kinetic Investigation of the Incorporation of Anti-Hepatitis B Nucleotide Analogues Catalyzed by Noncanonical Human DNA Polymerases journal December 2011
Structural and kinetic insights into binding and incorporation of L-nucleotide analogs by a Y-family DNA polymerase journal August 2014
Structural basis for the D-stereoselectivity of human DNA polymerase β journal April 2017
Visualizing the Molecular Interactions of a Nucleotide Analog, GS-9148, with HIV-1 Reverse Transcriptase–DNA Complex journal April 2010
Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance journal October 2009
Structure of a Covalently Trapped Catalytic Complex of HIV-1 Reverse Transcriptase: Implications for Drug Resistance journal November 1998
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta -branched amino acids journal August 1999
Structures of HIV-1 RT–DNA complexes before and after incorporation of the anti-AIDS drug tenofovir journal April 2004
Structural basis of HIV-1 resistance to AZT by excision journal September 2010
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. journal January 1997
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. journal August 1996
Human immunodeficiency virus reverse transcriptase and protease sequence database journal January 2003
Safety, Pharmacokinetics, and Efficacy of (+/−)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients journal July 2005
Telbivudine in the treatment of chronic hepatitis B journal February 2009
In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection journal February 2006
A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT journal January 2005
Trapping HIV-1 Reverse Transcriptase Before and After Translocation on DNA journal January 2003
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
A neutron-diffraction study of the low-cycle fatigue behaviour of an austenitic stainless steel 316 journal August 2010
PHENIX: a comprehensive Python-based system for macromolecular structure solution journal January 2010
Cavin1 intrinsically disordered domains are essential for fuzzy electrostatic interactions and caveola formation journal February 2021
PHENIX: a comprehensive Python-based system for macromolecular structure solution. text January 2010